This is not approved in many nations. But in process by insurance companies and other research.
Note that the starting dose of GLP-1, GLP-2 or GLP3 is grossly too high. Is this to make more money? This dose is extreme and only for rich obese patients. Even with no exercise or a change in cookies, over 70 pounds were lost. Muscle loss may cause lost buttock muscle and facial muscle loss, and needs to be addressed if using an older GLP1 (semaglutide), GLP2 (terzepatide), but also GLP3.
Lower more frequent dosing might preserve receptor function.
It is likely GLP4 and GLP5s may be coming.
GLP3
The triple agonist peptide retatrutide currently being investigated for its potential in managing obesity and type 2 diabetes by activating three key hormone receptors: GLP-1, GIP, and glucagon.
GLP-1 helps regulate blood sugar levels and suppress appetite.
GIP enhances insulin secretion and may contribute to weight loss.
Glucagon plays a role in energy expenditure and fat metabolism.
Retatrutide has shown promising results in clinical trials, with significant weight loss and improved metabolic health outcomes.
This is likely the most effective appetite dropping treatment we are tracking. It is likely much more effective than semaglutide GLP1 and tirzepatide GLP2.
If insulin resistant, food addicted, and obese–this may be a huge aid.
SAMPLE STUDY
Compared with placebo, participants who received retatrutide ≥4 mg reported greater reductions from baseline in overall appetite, hunger, and prospective food consumption…. Perceived Hunger and Disinhibition were greater in participants who received retatrutide 8 and 12 mg at Weeks 24 and 36. [I DOUBT THAT EVERYONE NEEDS THIS DOSE. AND WONDER IF LOWER DOSING MORE FREQUENTLY MIGHT BE BETTER].
Dietary Restraint increased versus placebo only in participants who received retatrutide 12 mg at Week 36.
[If you had] Reductions in … . Hunger [with] increases in Dietary Restraint you had reductions in body weight at Week 36
Source: Kanu C, Boye KS, Poon JL, Goetz I, Williamson S, Lou J, Hartman ML, Martin CK, Coskun T. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes Obes Metab. 2025 Dec;27(12):6988-6998. doi: 10.1111/dom.70097. Epub 2025 Sep 8. PMID: 40916752; PMCID: PMC12587234.